CrushSCI.com
126.8Average days
119Median days
4Fastest days
288Longest days
1332025 publications

Paper Review Records

All Paper Review Records

24 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

153 days

In Utero Exposure to Acetazolamide and Pregnancy Outcomes: A Cohort Study

Authors
Camille Reinaud; Maria Hoeltzenbein; Valérie Touitou; Catherine Vauzelle; Elisabeth Elefant; Delphine Beghin; Benoît Marin; Bénédicte CoulmShow moreShow less
Affiliations
1. AP-HP Sorbonne Université, Hôpital Pitié-Salpêtrière, Département de Santé Publique, Centre de Référence sur les Agents Tératogènes (CRAT), 75013 Paris, France; 2. Embryotox Center of Clinical Teratology and Drug Safety in Pregnancy, Institute of Clinical Pharmacology and Toxicology, Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin, Germany; 3. Limbach Genetics MVZ Humangenetik Bremen, Bremen, Germany; 4. Sorbonne Université, Hôpital Pitié-Salpêtrière, Département d’Ophtalmologie, 75013 Paris, France; 5. Sorbonne Université, INSERM, Institut Pierre-Louis d’Épidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Département de Santé Publique, Centre de Référence sur les Agents Tératogènes (CRAT), 75013 Paris, France; 6. Département Universitaire de Maïeutique, Sorbonne Université, Paris, FranceShow moreShow less
Source PDF DOI Publisher page
201 days

Medication-Related Osteonecrosis of the Jaw: An Unmasking Disproportionality Analysis of VigiBase, the WHO Spontaneous Reporting Database

Authors
Elena Arzenton; Antonia Marcianò; Federico Gozzi; Domenico Levita; Francesco Maccarrone; Ugo Moretti; Fabio Scapini; Gianluca Trifirò; Giacomo Oteri; Marco TuccoriShow moreShow less
Affiliations
1. Department of Diagnostics and Public Health, Section of Pharmacology, University of Verona, Verona, Italy; 2. Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, ItalyShow moreShow less
Source PDF DOI Publisher page
97 days

Discontinuation of Additional Risk Minimisation Measure Tools Implemented at Authorisation for Centrally Authorised Medicinal Products in the EU

Authors
Sharon C. M. Essink; Inge M. Zomerdijk; Valerie Strassmann; Thomas Goedecke; Sabine M. J. M. Straus; Helga Gardarsdottir; Marie L. De BruinShow moreShow less
Affiliations
1. Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands; 2. Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, The Netherlands; 3. European Medicines Agency, Amsterdam, The Netherlands; 4. Department of Clinical Pharmacy, University Medical Centre Utrecht, Utrecht, The Netherlands; 5. Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavik, IcelandShow moreShow less
Source PDF DOI Publisher page
188 days

Understanding the Relationship between Causality Assessment and Drug Labeling Practices: An Evaluation of US Regulations and FDA Policy Documents

Authors
Sarah Tanveer; Wendy Camelo Castillo; Linda Wastila; Tarek A. Hammad; Catherine E. Cooke; John P. A. Ioannidis; Peter DoshiShow moreShow less
Affiliations
1. Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, USA; 2. Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, USA; 3. Medical Safety for Marketed Products Development, Plasma-Derived Therapies, Medical Devices, and Vaccines, Takeda Development Center Americas, Inc., Cambridge, USA; 4. Departments of Medicine and of Epidemiology and Population Health, Stanford University, Stanford, USAShow moreShow less
Source PDF DOI Publisher page
86 days

Toward a Framework for Case Identification in Pharmacovigilance: Not All Reports are Created Equal

Authors
Michele Fusaroli; Joana Félix China; D. Sartori; Valentina Giunchi; Linda Härmark; Joep Scholl; Florence van Hunsel; G. Niklas Norén; Johan ElleniusShow moreShow less
Affiliations
1. Uppsala Monitoring Centre, Uppsala, Sweden; 2. Drug Safety Research Unit, Southampton, UK; 3. Netherlands Pharmacovigilance Centre Lareb, MH’s-Hertogenbosch, The Netherlands; 4. Department of PharmacoTherapy, Epidemiology, and Economics, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Groningen, The NetherlandsShow moreShow less
Source PDF DOI Publisher page
171 days

EudraScore: Modification of the Vigi4Eudra-score for the Assessment of the Completeness of Adverse Drug Reaction Reports in EudraVigilance

Authors
Diana Dubrall; Patrick Christ; Dennis Lex; Robert Hoffmann; Thomas Grüger; Matthias Schmid; Bernhardt SachsShow moreShow less
Affiliations
1. University of Bonn, University Hospital Bonn, Institute for Medical Biometry, Informatics and Epidemiology, Bonn, Germany; 2. Research Division, Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany; 3. Pharmacovigilance Division, Federal Institute for Drugs and Medical Devices, Bonn, Germany; 4. Department for Dermatology and Allergy, University Hospital RWTH Aachen, Aachen, GermanyShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does DRUG SAFETY take to review a manuscript?

As of 2026-11-18, CrushSCI has 24 complete review records for DRUG SAFETY. The fastest paper went from submission to acceptance in 4 days (ISoP MENA Chapter: Strategic Development and Future Directions Following a Decade of Strengthening Pharmacovigilance in the Middle East and North Africa, received 2026-08-16, accepted 2026-08-20); the slowest took 288 days. The average is 126.8 days and the median is 119 days. The fastest record has an unusually short interval; please check the original source.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.